GILD · News · 20260918N

Revenue Performance and Mix

GILEAD SCIENCES, INC. · 2026-09-18 · Importance 54 · Surprise 40 · No source text

Gilead Sciences’ revenue increased 10.6% year over year, according to the reported second-quarter update. The digest does not provide a dollar revenue amount or segment-level breakdown. The reported growth exceeds the 10% inclusion threshold for year-over-year metrics.

Key facts

• Gilead Sciences' revenue grew by 10.6% year-over-year. source
• Nykredit A/S purchased over 1.11 million shares of Gilead Sciences, Inc. valued at approximately $140.59 million during the second quarter. source
• Gilead's expansion of lenacapavir access in 14 Latin American and Caribbean countries may face revenue and margin constraints due to lower pricing in these markets. source
• Analysts maintain a "Moderate Buy" consensus rating for Gilead Sciences. source

Impact estimates